...89101112...203040...


Cell Therapy Processing Market Size, Share Growth, Trends, Devices, Applications, Competitive Analysis, Industry Expansion Strategies, By 2027 -…

The global Cell Therapy Processing market report provides geographic analysis covering regions, such as North America, Europe, Asia-Pacific, and Rest of the World. The Cell Therapy Processing market for each region is further segmented for major countries including the U.S., Canada, Germany, the U.K., France, Italy, China, India, Japan, Brazil, South Africa, and others.

FYI, You will get latest updated report as per the COVID-19 Impact on this industry. Our updated reports will now feature detailed analysis that will help you make critical decisions.

Browse Full Report: https://www.marketresearchengine.com/cell-therapy-processing-market

Cell therapy is the therapeutic application of cells despite cell kind or clinical indication a platform technology. Regenerative drugs is an approach to treating patients and so definitely not a platform technology. Its nearest to a hospital specialty, for example, medicine, medical specialty or palliative drugs, in alternative words platform technology independent. Its goals are ultimately to cure and so a paradigm shift away from typical symptom management and pain management. While its true that some cell therapies are regenerative, the bulk are not. Even as regenerative drugs is much larger than regenerative cell therapies alone, cell therapies collectively represent a market opportunity several orders of magnitude bigger than regenerative drugs. Equating one with the other is therefore not advantageous however instead will each a major disservice.

The global Cell Therapy Processing market is expected to exceed more than US$ 11.5 Billion by 2024, at a CAGR of 16.2% in the given forecast period.

Market Insights

The global Cell Therapy Processing market is segregated on the basis of Process as Cell Processing, Cell Preservation, Distribution, and Handling, and Process Monitoring and Quality Control. Based on Product Type the global Cell Therapy Processing market is segmented in Equipment, 1 Cell Processing Equipment, 2 Single-Use Equipment, 3 Other Equipment, Systems & Software, and Consumables. Based on End User the global Cell Therapy Processing market is segmented in Life Science Research Companies and Research Institutes.

Based on Cell Type, the global Cell Therapy Processing market is segmented in Human Cells, 1 Stem Cells, 2 Differentiated Cells, and Animal Cells.

Competitive Rivalry

Stemcell Technologies, Miltenyi Biotec GmbH, Beckman Coulter, Inc, Becton, Dickinson and Company, Ge Healthcare, Sartorius, Merck KGaA, Lonza Group, Thermo Fisher Scientific, Inc., Terumo Bct, Inc, and others are among the major players in the global Cell Therapy Processing market. The companies are involved in several growth and expansion strategies to gain a competitive advantage. Industry participants also follow value chain integration with business operations in multiple stages of the value chain.

The Cell Therapy Processing Market has been segmented as below:

The Cell Therapy Processing Market is segmented on the lines of Cell Therapy Processing Market, By Process, Cell Therapy Processing Market, By Product Type, Cell Therapy Processing Market, By End User, Cell Therapy Processing Market, By Cell Type, Cell Therapy Processing Market, By Region and Cell Therapy Processing Market, By Company.

Cell Therapy Processing Market, By Process this market is segmented on the basis of Cell Processing, Cell Preservation, Distribution, and Handling and Process Monitoring and Quality Control. Cell Therapy Processing Market, By Product Type this market is segmented on the basis of Equipment its covers 1 Cell Processing Equipment, 2 Single-Use Equipment & 3 Other Equipment. Systems & Software and Consumables. Cell Therapy Processing Market, By End User this market is segmented on the basis of Life Science Research Companies and Research Institutes. Cell Therapy Processing Market, By Cell Type this market is segmented on the basis of Human Cells its covers 1 Stem Cells & 2 Differentiated Cells. And Animal Cells. Cell Therapy Processing Market, By Region this market is segmented on the basis of North America, Europe, Asia-Pacific and Rest of the World. Cell Therapy Processing Market, By Company this market is segmented on the basis of Stemcell Technologies, Miltenyi Biotec GmbH, Beckman Coulter, Inc, Becton, Dickinson and Company, Ge Healthcare, Sartorius, Merck KGaA, Lonza Group, Thermo Fisher Scientific, Inc. and Terumo Bct, Inc.

The report covers:

Report Scope:

The global Cell Therapy Processing market report scope includes detailed study covering underlying factors influencing the industry trends.

The report covers analysis on regional and country level market dynamics. The scope also covers competitive overview providing company market shares along with company profiles for major revenue contributing companies.

The report scope includes detailed competitive outlook covering market shares and profiles key participants in the global Cell Therapy Processing market share. Major industry players with significant revenue share include Stemcell Technologies, Miltenyi Biotec GmbH , Beckman Coulter, Inc, Becton, Dickinson and Company, Ge Healthcare, Sartorius , Merck KGaA, , Lonza Group , Thermo Fisher Scientific, Inc., Terumo Bct, Inc, and others.

Reasons to Buy this Report:

Request Sample Report from here: https://www.marketresearchengine.com/cell-therapy-processing-market

Table of Contents:

5. Cell Therapy Processing Market, By Process

Other Related Market Research Reports:

Cell-based Assays Market 2019| Set for Rapid Growth During by 2024 MRE Report

Center Pivot Irrigation Systems Market 2019: Industry Demand, Size, Growth Report By 2024 Market Research Engine

About MarketResearchEngine.com

Market Research Engine is a global market research and consulting organization. We provide market intelligence in emerging, niche technologies and markets. Our market analysis powered by rigorous methodology and quality metrics provide information and forecasts across emerging markets, emerging technologies and emerging business models. Our deep focus on industry verticals and country reports help our clients to identify opportunities and develop business strategies.

Media Contact

Company Name: Market Research Engine

Contact Person: John Bay

Email: [emailprotected]

Phone: +1-855-984-1862

Country: United States

Website: https://www.marketresearchengine.com/

Read more here:

Cell Therapy Processing Market Size, Share Growth, Trends, Devices, Applications, Competitive Analysis, Industry Expansion Strategies, By 2027 -...

Longevity And Anti-Senescence Therapy Market Value Chain and Forecast COVID-19 2023 – Kentucky Journal 24

The global longevity and anti-senescence therapies market should grow from $329.8 million in 2018 to $644.4 million by 2023 with a compound annual growth rate (CAGR) of 14.3% during 2018-2023.

Report Scope:

The scope of this report is broad and covers various therapies currently under trials in the global longevity and anti-senescence therapy market. The market estimation has been performed with consideration for revenue generation in the forecast years 2018-2023 after the expected availability of products in the market by 2023. The global longevity and anti-senescence therapy market has been segmented by the following therapies: Senolytic drug therapy, Gene therapy, Immunotherapy and Other therapies which includes stem cell-based therapies, etc.

Request for Report Sample:https://www.trendsmarketresearch.com/report/sample/11698

Revenue forecasts from 2028 to 2023 are given for each therapy and application, with estimated values derived from the expected revenue generation in the first year of launch.

The report also includes a discussion of the major players performing research or the potential players across each regional longevity and anti-senescence therapy market. Further, it explains the major drivers and regional dynamics of the global longevity and anti-senescence therapy market and current trends within the industry.

The report concludes with a special focus on the vendor landscape and includes detailed profiles of the major vendors and potential entrants in the global longevity and anti-senescence therapy market.

Report Includes:

71 data tables and 40 additional tables An overview of the global longevity and anti-senescence therapy market Analyses of global market trends, with data from 2017 and 2018, and projections of compound annual growth rates (CAGRs) through 2023 Country specific data and analysis for the United States, Canada, Japan, China, India, U.K., France, Germany, Spain, Australia, Middle East and Africa Detailed description of various anti-senescence therapies, such as senolytic drug therapy, gene therapy, immunotherapy and other stem cell therapies, and their influence in slowing down aging or reverse aging process Coverage of various therapeutic drugs, devices and technologies and information on compounds used for the development of anti-ageing therapeutics A look at the clinical trials and expected launch of anti-senescence products Detailed profiles of the market leading companies and potential entrants in the global longevity and anti-senescence therapy market, including AgeX Therapeutics, CohBar Inc., PowerVision Inc., T.A. Sciences and Unity Biotechnology

Summary

Global longevity and anti-senescence therapy market deals in the adoption of different therapies and treatment options used to extend human longevity and lifespan. Human longevity is typically used to describe the length of an individuals lifetime and is sometimes used as a synonym for life expectancy in the demography. Anti-senescence is the process by which cells stop dividing irreversibly and enter a stage of permanent growth arrest, eliminating cell death. Anti-senescence therapy is used in the treatment of senescence induced through unrepaired DNA damage or other cellular stresses.

Global longevity and anti-senescence market will witness rapid growth over the forecast period (2018-2023) owing to an increasing emphasis on Stem Cell Research and an increasing demand for cell-based assays in research and development.

An increasing geriatric population across the globe and a rising awareness of antiaging products among generation Y and later generations are the major factors expected to promote the growth of global longevity and anti-senescence market. Factors such as a surging level of disposable income and increasing advancements in anti-senescence technologies are also providing traction to the global longevity and anti-senescence market growth over the forecast period (2018-2023).

According to the National Institutes of Health (NIH), the total geriatric population across the globe in 2016 was over REDACTED. By 2022, the global geriatric population (65 years and above) is anticipated to reach over REDACTED. An increasing geriatric population across the globe will generate huge growth prospectus to the market.

Senolytics, placenta stem cells and blood transfusions are some of the hot technologies picking up pace in the longevity and anti-anti-senescence market. Companies and start-ups across the globe such as Unity Biotechnology, Human Longevity Inc., Calico Life Sciences, Acorda Therapeutics, etc. are working extensively in this field for the extension of human longevity by focusing on study of genomics, microbiome, bioinformatics and stem cell therapies, etc. These factors are poised to drive market growth over the forecast period.

Global longevity and anti-senescence market is projected to rise at a CAGR of REDACTED during the forecast period of 2018 through 2023. In 2023, total revenues are expected to reach REDACTED, registering REDACTED in growth from REDACTED in 2018.

The report provides analysis based on each market segment including therapies and application. The therapies segment is further sub-segmented into Senolytic drug therapy, Gene therapy, Immunotherapy and Others. Senolytic drug therapy held the largest market revenue share of REDACTED in 2017. By 2023, total revenue from senolytic drug therapy is expected to reach REDACTED. Gene therapy segment is estimated to rise at the highest CAGR of REDACTED till 2023. The fastest growth of the gene therapy segment is due to the Large investments in genomics. For Instance; The National Human Genome Research Institute (U.S.) had a budget grant of REDACTED for REDACTED research projects in 2015, thus increasing funding to REDACTED for approximately REDACTED projects in 2016.

More Info of Impact Covid19@https://www.trendsmarketresearch.com/report/covid-19-analysis/11698

See original here:

Longevity And Anti-Senescence Therapy Market Value Chain and Forecast COVID-19 2023 - Kentucky Journal 24

Duvelisib May Reduce Lung Inflammation in Patients With COVID-19 – Targeted Oncology

Duvelisib (Copiktra), an anticancer drug, is currently being explored as treatment to reduce lung inflammation in hospitalized patients with coronavirus disease 2019 (COVID-19) in an investigator-initiated phase 2 study at the Winship Cancer Institute of Emory University.

The rationale behind the use of duvelisib is that the drug may be able to calm the systemic inflammation that exacerbates COVID-19-associated pneumonia and acute respiratory distress syndrome, stated principal investigator Edmund K. Waller, MD, PhD, professor, Hematology and Medical Oncology, Medicine and Pathology, Emory University School of Medicine, holder of Rein Saral, MD Professorship in Cancer Medicine, and medical director, Center for Stem Cell Processing and Apheresis, Emory University Hospital.

Pre-clinical data suggests that the agent can mitigate T cell exhaustion. More research has demonstrated T cell exhaustion limits the effectiveness of the immune system in fighting the infection.

Wallers lab has also previously tested whether duvelisib can enhance the activity of chimeric antigen receptor T-cell therapy in patients with cancer prior to the onset of the COVID-19 pandemic.

The phase 2 study will enroll 40 patients who are hospitalized with COVID-19-associated pneumonia. The trial is expected to last for 1 year. Every patient will receive either duvelisib or placebo for 2 weeks. Efficacy will be determined after 1 month. Patients will receive standard-of-care treatment and may receive antiviral medications, such as remdesivir (Veklury).

Waller is joined by co-investigators Aneesh K. Mehta, MD, and Marshall Lyon III, MD, infectious disease specialists, Emory Winship.

"This study is an example of how research on cancer immunology can be repurposed and deployed against COVID-19, possibly improving patient outcomes during this crisis," said Walter J. Curran, Jr, MD, the Lawrence W. Davis Chair, Radiation Oncology, Georgia Research Alliance Eminent Scholar, Chair in Cancer Research, and executive director, Winship, in a statement. "We are happy to be able to cooperate with our infectious disease and critical care colleagues in this effort."

The FDA previously granted approval to duvelisib in September 2018 for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Duvelisib can reduce levels of some of the same immune messenger cytokines that become elevated during a COVID-19 infection, according to previous data from patients with leukemia and lymphoma. In the phase 3 DUO trial (NCT02004522), the study in which the approval was based on, duvelisib reduced the risk of disease progression or death by 60% compared with ofatumumab (Arzerra) in patients with relapsed/refractory CLL/SLL who had received at least 2 prior lines of therapy.

Reference

Repurposing a cancer drug to reduce COVID-19 lung inflammation. News Release. July 13, 2020. Accessed July 16, 2020. https://bit.ly/2WpWrr2

See the original post:

Duvelisib May Reduce Lung Inflammation in Patients With COVID-19 - Targeted Oncology

Humanigen Expands Partnership with Catalent Biologics to Manufacture Investigational COVID-19 Therapeutic Candidate Lenzilumab – Business Wire

SOMERSET, N.J. & BURLINGAME, Calif.--(BUSINESS WIRE)--Catalent and Humanigen, Inc. (HGEN) (Humanigen) today announced the expansion of their relationship, under which Catalent will provide development, manufacturing and commercialization services for lenzilumab, Humanigens proprietary Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody.

Catalent is the leading global provider of advanced delivery technologies, development, manufacturing and clinical supply solutions for drugs, biologics, cell and gene therapies and consumer health products. Humanigen is a clinical stage biopharmaceutical company focused on preventing and treating cytokine storm with lenzilumab, the companys lead therapeutic candidate.

Mayo Clinic recently announced data on the first clinical use of lenzilumab in 12 patients with severe and critical COVID-19 pneumonia, the majority of whom showed rapid recovery and hospital discharge. A Phase 3 study is currently underway evaluating hospitalized COVID-19 patients.

Based on lenzilumabs promising clinical data, we are pleased to expand our relationship with Catalent to solidify our ability to manufacture and supply lenzilumab, commented Cameron Durrant, MD, MBA, Chief Executive Officer of Humanigen. If we are able to secure FDA approvals or Emergency Use Authorization, Catalent Biologics deep expertise and integrated OneBio solution will accelerate our ability to get this therapy to patients that need it most.

Catalent has partnered closely with Humanigen to develop and supply lenzilumab for clinical trials, commented Karen Flynn, President of Catalent Biologics and Chief Commercial Officer. The experience we already have with lenzilumab, and our OneBio integrated offering from development to supply, make Catalent uniquely suited to support Humanigen in the journey to make this promising therapy available to COVID-19 patients as soon as possible following receipt of regulatory approvals.

To date, Catalent Biologics has provided early-stage development and clinical cGMP drug substance manufacturing for lenzilumab at its facility in Madison, Wisconsin to support Humanigens ongoing clinical trials across various disease categories. Under the expanded partnership, Catalent is also providing clinical supply support for Humanigens Phase 3 potential registration study in COVID-19 from its Philadelphia facility.

Lenzilumab was originally manufactured in Catalents Madison facility using Catalent Biologics proprietary GPEx cell line development technology. As part of the expanded partnership, Catalent intends to provide additional drug substance clinical supply for Humanigens clinical trials, Expanded Access Program (EAP), as well as additional late-stage development and clinical and potential commercial drug substance manufacturing and vial filling at its Madison and Bloomington, Indiana, sites.

Catalent Biologics Madison facility provides development and drug substance manufacturing, including GPEx cell line development, process development, process validation, formulation development, and clinical and commercial cGMP manufacturing. Its Bloomington facility has deep expertise in sterile formulation, with drug substance development and manufacturing and drug product fill/finish capacity across liquid and lyophilized vials, prefilled syringes, and cartridges as well as primary and secondary packaging.

Catalents OneBio Suite is an integrated solution for the development, manufacturing, and supply of biologic drugs. Launched in May 2019, the suite of offerings is designed to integrate activities and accelerate timelines, reduce risk and simplify development with a single contract, program manager, and development timeline from cell line development to supply, with harmonized quality systems.

About Humanigen, Inc.

Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms. We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection. The companys immediate focus is to prevent or minimize the cytokine release syndrome that precedes severe lung dysfunction and ARDS in serious cases of SARS-CoV-2 infection. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. In addition, the company is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, bispecific or natural killer (NK) T cell engaging immunotherapy treatments to break the efficacy/toxicity linkage, including to prevent and/or treat graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Additionally, Humanigen and Kite, a Gilead Company, are evaluating lenzilumab in combination with Yescarta (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma in a clinical collaboration. For more information, visit http://www.humanigen.com.

About Catalent Biologics

Catalent Biologics is a global leader in development, manufacturing and analytical services for new biological entities, cell and gene therapies, biosimilars, sterile injectables, and antibody-drug conjugates. With over 20 years of proven expertise, Catalent Biologics has worked with 600+ mAbs and 80+ proteins, produced 13 biopharmaceutical drugs using GPEx cell line development technology, and manufactured 35+ commercially approved products. Catalent Cell & Gene Therapy, a unit of Catalent Biologics, is a full-service partner for adeno-associated virus (AAV) vectors and CAR-T immunotherapies, with deep experience in viral vector scale-up and production. Catalent recently acquired MaSTherCell, adding expertise in autologous and allogeneic cell therapy development and manufacturing. Catalent Cell & Gene Therapy has produced 100+ cGMP batches across 70+ clinical and commercial programs. For more information, visit biologics.catalent.com.

About Catalent

Catalent is the leading global provider of advanced delivery technologies, development, manufacturing, and clinical supply solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs over 13,500 people, including over 2,400 scientists and technicians, at more than 40 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com.

More products. Better treatments. Reliably supplied.

Humanigens Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual events or results may differ materially from those contained in the forward-looking statements. Words such as "will," "expect," "intend," "plan," "potential," "possible," "goals," "accelerate," "continue," and similar expressions identify forward-looking statements, including, without limitation, statements regarding our expectations for the Phase III study and the potential future development of lenzilumab to minimize or reduce the severity of lung dysfunction associated with severe and critical COVID-19 infections or to be approved by FDA for such use or to help CAR-T reach its full potential or to deliver benefit in preventing GvHD. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in our lack of profitability and need for additional capital to conduct the Phase III study and grow our business; our dependence on partners to further the development of our product candidates; the uncertainties inherent in the development and launch of any new pharmaceutical product; the outcome of pending or future litigation; and the various risks and uncertainties described in the "Risk Factors" sections and elsewhere in the Company's periodic and other filings with the Securities and Exchange Commission.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not place undue reliance on any forward-looking statements, which speak only as of the date of this release. We undertake no obligation to revise or update any forward-looking statements made in this press release to reflect events or circumstances after the date hereof or to reflect new information or the occurrence of unanticipated events, except as required by law.

More here:

Humanigen Expands Partnership with Catalent Biologics to Manufacture Investigational COVID-19 Therapeutic Candidate Lenzilumab - Business Wire

Research Roundup: Alzheimer’s Protective Gene and More – BioSpace

Every week there are numerous scientific studies published. Heres a look at some of the more interesting ones.

A Gene That Protects Against Alzheimers Disease

Researchers with Queen Mary University of London discovered a gene that naturally suppresses the signs of Alzheimers disease in human brain cells. They have also developed a rapid drug-screening system for treatment that might delay or prevent the disease. The researchers collected hair cells from people with Down syndrome (DS), who have about a 70% chance of developing Alzheimers in their lifetime. They reprogrammed them to become stem cells, which were then stimulated to become brain cells in a Petri dish. In the brain-like cells, they identified Alzheimers-like pathology. They found this could be used as an early preventative-drug testing platform. They published their research in the journal Molecular Psychiatry.

They then tested two different drugs known to inhibit beta-amyloid production, a hallmark of the disease, and tested them on the cultures. Within six weeks they appeared to prevent the Alzheimers-like pathology. The drugs themselves had already failed clinical trials, but they used them as proof-of-concept studies to show it could be used as a screening system. They also identified a naturally functioning Alzheimers suppressor gene (BACE2) that behaves like tumor suppressor genes in cancer.

Although its still early days, the system raises a theoretical possibility for further development as a tool to predict who might develop Alzheimers, said Dean Nizetic, lead researcher from Queen Mary University of London. The same stem cell process could be used on anyones hair follicles, the resulting brain cells of which may or may not then develop Alzheimers-pathology in the dish. The idea would be to catch the people at higher risk of early disease in a cell-based system, before it starts in a persons brain, and allow for the possibilities of individualized preventive interventions. We are still a long way from reaching this point.

Common Antibody Element in Best Response to COVID-19 Virus

Scientists with the The Scripps Research Institute, analyzing various human antibodies that appear to neutralize SARS-CoV-2, the virus that causes COVID-19, found a common molecule in them. They reviewed data from almost 300 anti-COVID-19 antibodies that their laboratories and others have identified in convalescent COVID-19 patients in the last few months. A subset of them were especially effective at neutralizing the virus. And what they had in common was a gene, IGHV3-53. Previous research suggested that antibodies encoded by IGHV3-53 are typically present, sometimes in small numbers, in the blood of healthy people. The gene encoded for about 10% of the 294 antibodies analyzed, and they found that these antibodies contained an unusually short variation of the CDR H3 loop, which is normally a key target-binding element. Nonetheless, they are very potent against SARS-CoV-2 compared to other antibodies that are not encoded by that specific gene. The researchers believe this will provide not only a better understanding of the virus and how antibodies attack them but could guide future vaccine development.

A Cancer Vaccine to Activate the Immune System Against Broad Range of Cancers

Scientists with the Translational Research Institute developed a new vaccine in collaboration with The University of Queensland that appears to activate the immune system against numerous cancers, including leukemia, breast cancer, lung cancer and pancreatic cancers. The vaccine is made up of human antibodies fused with tumor-specific protein. The advantage of this approach over existing cancer vaccines is it can be produced off the shelf and the prototype targets the key tumor cells required for initiation of tumor-specific immune responses, which should maximize their potential effectiveness.

Finding the Fountain of Youth

Investigators at the University of Southern California found that the drug mifepristone can extend the lives of two different species in laboratory studiesthe fruit fly and roundworms. The drug, also known as RU-486, is used to end early pregnancies and to treat cancer and Cushing disease. The drug appears to affect certain metabolic pathways that involve a juvenile hormone. The researchers believe there may be similar results in humans, although a better understanding of how the drug actually extends lifespan in fruit flies and roundworms would be necessary.

Gene IDed that is Responsible for Glioblastoma Brain Cancer

Researchers at the University of Virginia Health System identified an oncogene that is responsible for glioblastoma, the deadliest form of brain cancer. The gene, AVIL, typically helps cells maintain their size and shape. But under certain conditions, it can shift into overdrive, which causes cancer cells to grow and metastasize. In laboratory mice, they blocked the genes activity, which destroyed the glioblastoma cells but did not affect healthy cells. They found that AVIL is overexpressed in 100% of glioblastoma cells and clinical samples but is hardly expressed in normal cells and tissues.

New Technique Could Make CRISPR Even Better

CRISPR gene editing is a biological revolution, but researchers keep finding ways to improve on it. Investigators at Cornell University identified a protein called AcrVIA1, which is found in Listeria bacteria in soil, that can halt the CRISPR-Cas13 editing process. This can be useful in controlling CRISPR-Cas13 editing and has the potential to be applicable to COVID-19 research, because CRISPR-Cas13 can be used to edit RNA and SARS-CoV-2 is an RNA virus.

Large Study Used Umbilical Cord Blood to Successfully Treat Rare Genetic Disorders

Scientists at UPMC Childrens Hospital of Pittsburgh used umbilical cord blood to safely and effectively treat 44 children born with a number of non-cancerous genetic disorders, including sickle cell, thalassemia, Hunter syndrome, Krabbe disease, metachromatic leukodystrophy (MLD) and other immune deficiencies. The goal was to develop a somewhat universal treatment. The research was published in Blood Advances.

There has been a lot of emphasis placed on cool new technologies that might address these diseases, buteven if they prove effectivethose arent available to most centers, said Paul Szabolcs, senior author and division director of bone marrow transplantation and cellular therapies at UPMC Childrens. The regimen we developed is more robust, readily applicable and will remain significantly less expensive.

Continue reading here:

Research Roundup: Alzheimer's Protective Gene and More - BioSpace

Animal Stem Cell Therapy Market size and Key Trends in terms of volume and value 2019-2025 – 3rd Watch News

Animal Stem Cell Therapy Market 2018: Global Industry Insights by Global Players, Regional Segmentation, Growth, Applications, Major Drivers, Value and Foreseen till 2024

The recent published research report sheds light on critical aspects of the global Animal Stem Cell Therapy market such as vendor landscape, competitive strategies, market drivers and challenges along with the regional analysis. The report helps the readers to draw a suitable conclusion and clearly understand the current and future scenario and trends of global Animal Stem Cell Therapy market. The research study comes out as a compilation of useful guidelines for players to understand and define their strategies more efficiently in order to keep themselves ahead of their competitors. The report profiles leading companies of the global Animal Stem Cell Therapy market along with the emerging new ventures who are creating an impact on the global market with their latest innovations and technologies.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2726754&source=atm

The recent published study includes information on key segmentation of the global Animal Stem Cell Therapy market on the basis of type/product, application and geography (country/region). Each of the segments included in the report is studies in relations to different factors such as market size, market share, value, growth rate and other quantitate information.

The competitive analysis included in the global Animal Stem Cell Therapy market study allows their readers to understand the difference between players and how they are operating amounts themselves on global scale. The research study gives a deep insight on the current and future trends of the market along with the opportunities for the new players who are in process of entering global Animal Stem Cell Therapy market. Market dynamic analysis such as market drivers, market restraints are explained thoroughly in the most detailed and easiest possible manner. The companies can also find several recommendations improve their business on the global scale.

The readers of the Animal Stem Cell Therapy Market report can also extract several key insights such as market size of varies products and application along with their market share and growth rate. The report also includes information for next five years as forested data and past five years as historical data and the market share of the several key information.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2726754&source=atm

Segment by Type, the Animal Stem Cell Therapy market is segmented intoDogsHorsesOthers

Segment by Application, the Animal Stem Cell Therapy market is segmented intoVeterinary HospitalsResearch Organizations

Regional and Country-level Analysis:North AmericaUnited StatesCanadaAsia-PacificChinaJapanSouth KoreaIndiaSoutheast AsiaAustraliaRest of Asia-PacificEuropeGermanyFranceU.K.ItalyRussiaNordic CountriesRest of EuropeLatin AmericaMexicoBrazilRest of Latin AmericaMiddle East & AfricaTurkeySaudi ArabiaUAERest of MEA

Competitive Landscape and Animal Stem Cell Therapy Market Share AnalysisAnimal Stem Cell Therapy market competitive landscape provides details and data information by companies. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on sale and revenue by players for the period 2015-2020. Details included are company description, major business, Animal Stem Cell Therapy product introduction, recent developments, Animal Stem Cell Therapy sales by region, type, application and by sales channel.

The major companies include:Medivet Biologics LLCVETSTEM BIOPHARMAJ-ARMU.S. Stem Cell, IncVetCell TherapeuticsCelavet Inc.Magellan Stem CellsKintaro Cells PowerAnimal Stem CareAnimal Cell TherapiesCell Therapy SciencesAnimacel

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2726754&licType=S&source=atm

Some of the Major Highlights of TOC covers in Animal Stem Cell Therapy Market Report:

Chapter 1: Methodology & Scope of Animal Stem Cell Therapy Market

Chapter 2: Executive Summary of Animal Stem Cell Therapy Market

Chapter 3: Animal Stem Cell Therapy Industry Insights

Chapter 4: Animal Stem Cell Therapy Market, By Region

Chapter 5: Company Profile

And Continue

Originally posted here:

Animal Stem Cell Therapy Market size and Key Trends in terms of volume and value 2019-2025 - 3rd Watch News

Adipose Derived Stem Cell Therapy Market : Latest Innovations, Drivers and Industry Key Events 2019-2025 Bulletin Line – Bulletin Line

Study of the Global Adipose Derived Stem Cell Therapy Market

The recently published market study on the global Adipose Derived Stem Cell Therapy market provides a detailed analysis of the various factors that are expected to impact the growth of the Adipose Derived Stem Cell Therapy market in the upcoming years. As per the report, the Adipose Derived Stem Cell Therapy market is set to grow at a CAGR of ~XX% during the assessment period (2019-2029) and exceed the value of ~US$XX% by the end of 2029.

The report offers a granular assessment of the various segments and sub-segments of the Adipose Derived Stem Cell Therapy market and the data is depicted in the form of tables, figures, and graphs. Readers can leverage the data enclosed in the report to formulate effective business strategies to enhance their position in the Adipose Derived Stem Cell Therapy market landscape.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.researchmoz.com/enquiry.php?type=S&repid=2694812&source=atm

Essential Findings of the Report

Bifurcation of the Global Adipose Derived Stem Cell Therapy Market

segment by Type, the product can be split intoAutologous Stem CellsAllogeneic Stem CellsMarket segment by Application, split intoTherapeutic ApplicationResearch Application

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaJapanSoutheast AsiaIndiaCentral & South America

The study objectives of this report are:To analyze global Adipose Derived Stem Cell Therapy status, future forecast, growth opportunity, key market and key players.To present the Adipose Derived Stem Cell Therapy development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Adipose Derived Stem Cell Therapy are as follows:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year 2020 to 2026For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2694812&source=atm

The report aims to resolve the following doubts related to the Adipose Derived Stem Cell Therapy market:

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2694812&licType=S&source=atm

Excerpt from:

Adipose Derived Stem Cell Therapy Market : Latest Innovations, Drivers and Industry Key Events 2019-2025 Bulletin Line - Bulletin Line

Rheumatoid Arthritis Stem Cell Therapy Market Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 to 2028 – Cole of Duty

An exclusive market study published by Fact.MR on the Rheumatoid Arthritis Stem Cell Therapy market offers insights related to how the market is projected to grow over the forecast period (2019-2029). The objective of the report is to enable our readers to understand the various aspects of the Rheumatoid Arthritis Stem Cell Therapy market and assist them to formulate impactful business strategies. Furthermore, the different factors that are expected to influence the current and future dynamics of the Rheumatoid Arthritis Stem Cell Therapy market are discussed in the presented study.

According to the report, the Rheumatoid Arthritis Stem Cell Therapy market is set to reach a market value of ~US$ XX by the end of 2029 and register a CAGR growth of ~XX% during the assessment period. The report offers an in-depth understanding of the Rheumatoid Arthritis Stem Cell Therapy supply chain, value, and volume chain across the various regional markets.

Request Sample Report @ https://www.factmr.co/connectus/sample?flag=S&rep_id=1001

Important Insights Enclosed in the Report:

The published report provides a deep understanding of the Rheumatoid Arthritis Stem Cell Therapy market by segregating the market into different segments such as region, application, and end-use industry.

Request Methodology On This Report @ https://www.factmr.co/connectus/sample?flag=RM&rep_id=1001

Rheumatoid Arthritis Stem Cell Therapy Market Segmentation

By Region

The regional analysis of the Rheumatoid Arthritis Stem Cell Therapy market dives deep to understand the market scenario in different regions. The market size, share, and value of each regional market is analyzed and presented in the report along with informative tables and figures.

By Application

The report offers a clear picture of how the Rheumatoid Arthritis Stem Cell Therapy is utilized in various applications. The different applications covered in the report include:

By End-Use Industry

The end-use industry assessment throws light on the consumption of the Rheumatoid Arthritis Stem Cell Therapy across various end-use industries including:

Competitive landscape

Ask analyst about this report at https://www.factmr.co/connectus/sample?flag=AE&rep_id=1001

Important queries addressed in the Rheumatoid Arthritis Stem Cell Therapy market report:

Reasons to Choose Fact.MR

Originally posted here:

Rheumatoid Arthritis Stem Cell Therapy Market Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 to 2028 - Cole of Duty

Corona impact on Stem Cell Banking Market 2020 By Manufacturers, Regions, Type And Application, Forecast To 2025| CCBC, CBR, ViaCord, Esperite,…

The global Stem Cell Banking Market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Stem Cell Banking Market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the global Stem Cell Banking Market. With qualitative and quantitative analysis, we help you with thorough and comprehensive research on the global Stem Cell Banking Market. We have also focused on SWOT, PESTLE, and Porters Five Forces analyses of the global Stem Cell Banking Market.

Leading players of the global Stem Cell Banking Market are analyzed taking into account their market share, recent developments, new product launches, partnerships, mergers or acquisitions, and markets served. We also provide an exhaustive analysis of their product portfolios to explore the products and applications they concentrate on when operating in the global Stem Cell Banking Market. Furthermore, the report offers two separate market forecasts one for the production side and another for the consumption side of the global Stem Cell Banking Market. It also provides useful recommendations for new as well as established players of the global Stem Cell Banking Market.

Final Stem Cell Banking Report will add the analysis of the impact of COVID-19 on this Market.

Stem Cell Banking Market competition by top manufacturers/Key player Profiled:CCBC, CBR, ViaCord, Esperite, Vcanbio, Boyalife, LifeCell, Crioestaminal, RMS Regrow, Cordlife Group, PBKM FamiCord, cells4life, Beikebiotech, StemCyte, Cryo-cell, Cellsafe Biotech Group, PacifiCord, Americord, Krio, Familycord, Cryo Stemcell, Stemade Biotech

>>> Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Stem Cell Banking Market:

The global Stem Cell Banking market was valued at $XX million in 2019, and MAResearch analysts predict the global market size will reach $XX million by the end of 2029, growing at a CAGR of XX% between 2019 and 2029.

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 210 countries and territories around the world and 2 international conveyances. The global impacts of COVID-19 are already starting to be felt, and will significantly affect this industry in 2020.

This report analyses the impact of COVID-19 on this industry. COVID-19 can affect the global market in 3 ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on enterprises and financial markets.

This report provides detailed historical analysis of global market for Stem Cell Banking from 2014-2019, and provides extensive market forecasts from 2020-2029 by region/country and subsectors. It covers the sales volume, price, revenue, gross margin, historical growth and future perspectives in the Stem Cell Banking market.

Segmentation by Product:

Umbilical Cord Blood Stem CellEmbryonic Stem CellAdult Stem CellOther

Segmentation by Application:

Diseases TherapyHealthcare

Competitive Analysis:

Global Stem Cell Banking Market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of Stem Cell Banking Market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Scope of the Report:The all-encompassing research weighs up on various aspects including but not limited to important industry definition, product applications, and product types. The pro-active approach towards analysis of investment feasibility, significant return on investment, supply chain management, import and export status, consumption volume and end-use offers more value to the overall statistics on the Stem Cell Banking Market. All factors that help business owners identify the next leg for growth are presented through self-explanatory resources such as charts, tables, and graphic images.

The report offers in-depth assessment of the growth and other aspects of the Stem Cell Banking market in important countries (regions), including:

North America(United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)

South America (Brazil, Argentina, Colombia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Our industry professionals are working reluctantly to understand, assemble and timely deliver assessment on impact of COVID-19 disaster on many corporations and their clients to help them in taking excellent business decisions. We acknowledge everyone who is doing their part in this financial and healthcare crisis.

For Customised Template PDF Report:https://www.reporthive.com/request_customization/2377409

Table of Contents

Report Overview:It includes major players of the global Stem Cell Banking Market covered in the research study, research scope, and Market segments by type, market segments by application, years considered for the research study, and objectives of the report.

Global Growth Trends:This section focuses on industry trends where market drivers and top market trends are shed light upon. It also provides growth rates of key producers operating in the global Stem Cell Banking Market. Furthermore, it offers production and capacity analysis where marketing pricing trends, capacity, production, and production value of the global Stem Cell Banking Market are discussed.

Market Share by Manufacturers:Here, the report provides details about revenue by manufacturers, production and capacity by manufacturers, price by manufacturers, expansion plans, mergers and acquisitions, and products, market entry dates, distribution, and market areas of key manufacturers.

Market Size by Type:This section concentrates on product type segments where production value market share, price, and production market share by product type are discussed.

Market Size by Application:Besides an overview of the global Stem Cell Banking Market by application, it gives a study on the consumption in the global Stem Cell Banking Market by application.

Production by Region:Here, the production value growth rate, production growth rate, import and export, and key players of each regional market are provided.

Consumption by Region:This section provides information on the consumption in each regional market studied in the report. The consumption is discussed on the basis of country, application, and product type.

Company Profiles:Almost all leading players of the global Stem Cell Banking Market are profiled in this section. The analysts have provided information about their recent developments in the global Stem Cell Banking Market, products, revenue, production, business, and company.

Market Forecast by Production:The production and production value forecasts included in this section are for the global Stem Cell Banking Market as well as for key regional markets.

Market Forecast by Consumption:The consumption and consumption value forecasts included in this section are for the global Stem Cell Banking Market as well as for key regional markets.

Value Chain and Sales Analysis:It deeply analyzes customers, distributors, sales channels, and value chain of the global Stem Cell Banking Market.

Key Findings: This section gives a quick look at important findings of the research study.

About Us:Report Hive Research delivers strategic market research reports, statistical surveys, industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of global business leaders, government organizations, SMEs, individuals and Start-ups, top management consulting firms, universities, etc. Our library of 700,000 + reports targets high growth emerging markets in the USA, Europe Middle East, Africa, Asia Pacific covering industries like IT, Telecom, Semiconductor, Chemical, Healthcare, Pharmaceutical, Energy and Power, Manufacturing, Automotive and Transportation, Food and Beverages, etc. This large collection of insightful reports assists clients to stay ahead of time and competition. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio, and application analysis, etc.

Contact Us:

Report Hive Research

500, North Michigan Avenue,

Suite 6014,

Chicago, IL 60611,

United States

Website: https://www.reporthive.com

Email: [emailprotected]

Phone: +1 312-604-7084

Link:

Corona impact on Stem Cell Banking Market 2020 By Manufacturers, Regions, Type And Application, Forecast To 2025| CCBC, CBR, ViaCord, Esperite,...

Stem Cell Therapy Market Size, Market Share, Leading Players and Forecast to 2022 – 3rd Watch News

Stem Cell Therapy Market is worth USD 11.99 billion in 2016 and is expected to reach USD 60.94 billion by 2022, growing at a CAGR of 31.1% from 2016 to 2022.

The global stem cell therapy market report offers in-depth analysis of the market size (revenue), market share, major market segments, different geographic regions, forecast for the next five years, key market players, and premium industry trends. It also focuses on the key drivers, restraints, opportunities and challenges in the stem cell therapy market.

Download Sample of This Strategic Report:https://www.kennethresearch.com/sample-request-10325644

KEY BENEFITS OF THE REPORT:Deeper understanding of the strategies adopted by the key players in this market to stay competitiveGranular analysis about the growth map of the market during the next five yearsComprehensive analysis of the key market players and their market share

KEY PREMIUM INDUSTRY INSIGHTS:The increasing government initiatives and funding from various organizations, the increased spending on research and development, rapid technological advancement in genomics, and the rising awareness about the stem cell therapy are some of the factors fuelling the growth of the stem cell therapy market.

Other factors, such as the robust product pipelines and increasing approval of the new clinical trials are fuelling the growth of the stem cell therapy market further.However, improper infrastructure, insufficient storage systems, and ethical problems are the major restraints for the stem cell therapy market.

MARKET SEGMENTATION:This report analyzes the stem cell therapy market by the following segments:

Stem Cell Therapy Market, by TreatmentsAllogeneic Stem Cell TherapyAutologous Stem Cell TherapyStem Cell Therapy Market, by ApplicationsOncologyCentral Nervous System DiseasesEye DiseasesMusculoskeletal DiseasesWound & InjuriesMetabolic DisordersCardiovascular DisordersImmune System DisordersStem Cell Therapy Market, by End-usersHospitalsAmbulatory Surgical Centers

Request For Full Report:https://www.kennethresearch.com/sample-request-10325644

KEY MARKET PLAYERS:Key players in the stem cell therapy market include:

Vericel Corporation.Stem Cells, Inc.Mesoblast, Ltd.Gamida CellOsiris Therapeutics, Inc.Chiesi Farmaceutici S.p.AReNeuron Group, plc

About Kenneth Research

Kenneth Research is a reselling agency providing market research solutions in different verticals such as Automotive and Transportation, Chemicals and Materials, Healthcare, Food & Beverage and Consumer Packaged Goods, Semiconductors, Electronics & ICT, Packaging, and Others. Our portfolio includes set of market research insights such as market sizing and market forecasting, market share analysis and key positioning of the players (manufacturers, deals and distributors, etc), understanding the competitive landscape and their business at a ground level and many more. Our research experts deliver the offerings efficiently and effectively within a stipulated time. The market study provided by Kenneth Research helps the Industry veterans/investors to think and to act wisely in their overall strategy formulation

Contact Us

Kenneth Research

Email : [emailprotected]

Phone: +1 313 462 0609

Continued here:

Stem Cell Therapy Market Size, Market Share, Leading Players and Forecast to 2022 - 3rd Watch News

Canine Stem Cell Therapy Market 2019 Analysis, Industry Size, Share Leaders, Current Status by Major vendors and Trends by Forecast to 2023 – 3rd…

The global Canine Stem Cell Therapy market is forecasted to reach a market value of ~US$ XX Mn/Bn by the end of 2029 registering a CAGR growth of around XX% during the forecast period (2019-2029). The recent market report provides a detailed analysis of the current structure of the Canine Stem Cell Therapy market along with the estimated trajectory of the market over the course of the stipulated timeframe.

The report provides an in-depth assessment of the numerous factors that are anticipated to impact the market dynamics with utmost precision and accuracy. The SWOT and Porters Five Forces Analysis provides a clear picture about the current operations of the various market players operating in the global Canine Stem Cell Therapy market.

Request Sample Report @https://www.mrrse.com/sample/16152?source=atm

The Canine Stem Cell Therapy market report portrays the market share and the application of each of the sub-segments across various verticals.

The Canine Stem Cell Therapy market report explains how the Canine Stem Cell Therapy is being deployed in different sector.

Competitive landscape:

The report ponders over the market scenario in various geographies and highlights the major opportunities, trends, and challenges faced by market players in each region. An in-depth country wise analysis of each major region provides readers a deep understanding of the regional aspects of the market including, the market share, pricing analysis, revenue growth, and more.

Market Taxonomy

The global canine stem cell therapy market has been segmented into:

Product Type:

Application:

End User:

Region:

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/16152?source=atm

The market report on the Canine Stem Cell Therapy market addresses some important questions such as:

Crucial data enclosed in the report:

Buy This Report @ https://www.mrrse.com/checkout/16152?source=atm

See the article here:

Canine Stem Cell Therapy Market 2019 Analysis, Industry Size, Share Leaders, Current Status by Major vendors and Trends by Forecast to 2023 - 3rd...

US Stem Cell Therapy Market 2020 Research on Import-Export Details, Business Standards and Forecast to 2025 – Owned

Stem Cell Therapy Market Research Report Cover Covid-19 Outbreak:

Brand Essence Market Research has developed a concise study on the Stem Cell Therapy market to depict valuable insights related to significant market trends driving the industry. The report features analysis based on key opportunities and challenges confronted by market leaders while highlighting their competitive setting and corporate strategies for the estimated timeline.

Download Premium Sample of the Report: https://brandessenceresearch.biz/Request/Sample?ResearchPostId=72717&RequestType=Sample

TheMajorPlayersCovered in this Report:Gilead,Novartis,Organogenesis,Vericel & More.

Product Type: Adult Stem Cells,Human Embryonic Stem Cells (hESC),Induced Pluripotent Stem Cells,Very Small Embryonic Like Stem Cells

Application: Regenerative Medicine,Drug Discovery and Development

Results of the recent scientific undertakings towards the development of new Stem Cell Therapy products have been studied. Nevertheless, the factors affecting the leading industry players to adopt synthetic sourcing of the market products have also been studied in this statistical surveying report. The conclusions provided in this report are of great value for the leading industry players. Every organization partaking in the global production of the Stem Cell Therapy market products have been mentioned in this report, in order to study the insights on cost-effective manufacturing methods, competitive landscape, and new avenues for applications.

Global Stem Cell TherapyMarket: Regional SegmentationFor further clarification, analysts have also segmented the market on the basis of geography. This type of segmentation allows the readers to understand the volatile political scenario in varying geographies and their impact on the global Stem Cell Therapymarket. On the basis of geography, the global market for Stem Cell Therapyhas been segmented into:

North America(United States, Canada, and Mexico)Europe(Germany, France, UK, Russia, and Italy)Asia-Pacific(China, Japan, Korea, India, and Southeast Asia)South America(Brazil, Argentina, Colombia, etc.)Middle East and Africa(Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Request Cutomization @https://brandessenceresearch.biz/Request/Sample?ResearchPostId=72717&RequestType=Methodology

Report Methodology:

The information enclosed in this report is based upon both primary and secondary research methodologies.

Primary research methodology includes the interaction with service providers, suppliers, and industry professionals. Secondary research methodology includes a meticulous search of pertinent publications like company annual reports, financial reports, and exclusive databases.

Table of Content:

Market Overview: The report begins with this section where product overview and highlights of product and application segments of the Global Stem Cell Therapy Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition by Company: Here, the competition in the Worldwide Global Stem Cell Therapy Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data: As the name suggests, this section gives the sales data of key players of the Global Stem Cell Therapy Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the Global Stem Cell Therapy Market.

Market Status and Outlook by Region: In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the Global Stem Cell Therapy Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User: This section of the research study shows how different end-user/application segments contribute to the Global Stem Cell Therapy Market.

Market Forecast: Here, the report offers a complete forecast of the Global Stem Cell Therapy Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion: This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Top Trending Reports:

https://teletype.in/@supriyakoshti1997/YmlOpc9bP

https://teletype.in/@pranoti/PUPYv8bid

https://elink.io/91f105a

https://adalidda.com/posts/2tW6xipaLSyCdza3h/online-gambling-market-2020-industry-scenario-strategies

https://teletype.in/@ellinahussey/hz3434OI5

https://brandessenceresearch.biz/Automotive-and-Transport/Identity-and-Access-Management-IAM-Market-Size/Summary

Continue reading here:

US Stem Cell Therapy Market 2020 Research on Import-Export Details, Business Standards and Forecast to 2025 - Owned

A ‘safety switch’ for cell therapy based on nutrient deprivation – FierceBiotech

The early success of CAR-T cell therapies in treating some forms of blood cancer has sent oncology researchers on a quest to develop the technology to address a range of tumor types. But the risk that the modified immune cells could cause the potentially deadly side effect known as cytokine release syndrome has prompted an equally enthusiastic effort in the research community to find innovative ways to combat that problem.

London-based startup Auxolytic is developing safety switches for cell therapy that hingeon depriving them of nutrientsthey need to survive. The company was founded by University of Cambridge biochemist James Patterson, Ph.D., who is working with researchers at Stanford University to develop the switch.

In a new study, the researchers demonstrated their technique with a gene called UMPS that normally makes the nutrient uridine, which T cells need to grow and proliferate. When they knocked out the gene in human T cells and pluripotent stem cells, the cells became inactive within a week, they reported in the journal Nature Biotechnology.

White Paper: Keep Your GI Trials Moving During COVID-19

Clinical Inks intimate knowledge of and experience with GI trials enables a better deployment experience and improved trial conduct. Learn how our GI-specific data capture solutions can support virtual and hybrid trials during COVID-19.

How would this work in people? The UMPS gene would be knocked out in the cell therapy during the engineering process, and then the patient receiving the treatment would take uridine supplements to replace the missing nutrient. If signs of side effects to the cell therapy emerge, the patient would stop taking the supplement.

RELATED: Improving CAR-T therapy for cancer by regulating 2 proteins

Auxolytic tested its technology in mice by treating them with UMPS-edited T cells and then monitoring them for the rejection response graft versus host disease (GvHD). The cells became inactive in the mice that were not fed uridine supplements.

Its the latest idea to emerge for improving the safety of cell therapies. Earlier this year, a team at the University of North Carolina at Chapel Hill published a study showing they could dampen cytokine release syndrome by modulating levels of an enzyme called SHP1. Last year, German scientists showed that Bristol Myers Squibbs leukemia drug Sprycel could temporarily pause the activity of CAR-T cells in mice, preventing cytokine release.

Auxolytic gets its name from a scientific principle called auxotrophy, which refers to the ability of cells to synthesize nutrients and other compounds they need to survive, Patterson explained in a statement. Pattersons goal is to work with CAR-T developers to incorporate the technology into their products, he said.

See more here:

A 'safety switch' for cell therapy based on nutrient deprivation - FierceBiotech

Global Stem Cell Therapy Market Growth, Share, Demand and Applications Forecast to 2024 – 3rd Watch News

The Global Stem Cell Therapy Market report is deep study of the present market dynamics. It consists of the detailed study of current market trends along with the past statistics. The past years are considered as reference to get the predicted data for the forecasted period. Various important factors such as market trends, revenue growth patterns market shares and demand and supply are included in almost all the market research report for every industry. A significant development has been recorded by the market of Stem Cell Therapy, in past few years. It is also for it to grow further. Various important factors such as market trends, revenue growth patterns market shares and demand and supply are included in almost all the market research report for every industry. A systematized methodology is used to make a Report on the Global Stem Cell Therapy market. For the analysis of market on the terms of research strategies, these techniques are helpful. All the information about the Products, manufacturers, vendors, customers and much more is covered in research reports.

Request a sample of this report @ https://www.orbispharmareports.com/sample-request/14043?utm_source=Nilam

There are different marketing strategies that every marketer looks up to in order to ace the competition in the Global Stem Cell Therapy market. Some of the primary marketing strategies that is needed for every business to be successful are Passion, Focus, Watching the Data, Communicating the value To Your Customers, Your Understanding of Your Target Market. There is a target set in market that every marketing strategy has to reach. The study is done with the help of analysis such as SWOT analysis and PESTEL analysis. SWOT analysis includes the study of Threats, weaknesses, strengths and opportunities that the Stem Cell Therapy market. Whereas PESTEL analysis is the study concerning Economic, Technological, legal political, social, environmental matters. For the analysis of market on the terms of research strategies, these techniques are helpful.

Browse the complete report @ https://www.orbispharmareports.com/global-stem-cell-therapy-market-2019-present-status-and-future-opportunities-by-major-companies-typs-and-applications-2024/?utm_source=Nilam

Potential consumers, market values, and the future scope for the Stem Cell Therapy market are explained thoroughly to the users in this report. The key players of Stem Cell Therapy industry, their product portfolio, market share, industry profiles is studied in this report. It is very important for the vendors to provide customers with new and improved product/ services in order to gain their loyalty.

Segmentation by Type:

AutologousAllogeneic

Segmentation by Application:

Musculoskeletal DisorderWounds & InjuriesCorneaCardiovascular DiseasesOthers

The study of various segments of the global Stem Cell Therapy market are also covered in the research report. In addition to that, for the forecast periods determination of factors like market size and the competitive landscape of the market is analyzed in the report. Due to the increasing globalization and digitization, there are new trends coming to the market every day. The research report provides the in-depth analysis of all these trends.

Make an enquiry of this report @ https://www.orbispharmareports.com/enquiry-before-buying/14043?utm_source=Nilam

About Us :

At Orbispharma we curate the most relevant news stories, features, analysis and research reports on the important challenges undertaken by the pharmaceutical and related sectors. Our editorial philosophy is to bring you sharp, focused and informed perspective of industries, the end users and application of all upcoming trends into the pharma sector. Orbispharma believes in conversations that can bring a change in one of the most crucial economic sectors in the world. With these conversations we wish our customers to make sound business decisions with right business intelligence.

Contact Us :

View original post here:

Global Stem Cell Therapy Market Growth, Share, Demand and Applications Forecast to 2024 - 3rd Watch News

COVID-19 Impact On Global Stem Cell Therapy Market Research Report Strategies, Shares, Trends, Growth Analysis Forecast to 2027 – Daily Research…

"Global Thoracic Catheters Market Assessment Report: Present & Forecast Evaluation"is a comprehensive blend of qualitative and quantitative analysis in terms of Thoracic Catheters market size, demand, revenue, gross margin, value, and volume. The whole research study is segmented based on regions, product type, application, and top companies operating in Thoracic Catheters Market. The report begins with the introduction on Thoracic Catheters Industry, drivers, restraints, trends, PEST analysis, PORTERs Five Forces analysis. The macro-economic factors, Thoracic Catheters manufacturing cost, industry chain structure and pricing analysis are conducted. The pandemic impact in terms of production, demand, profit, growth scope is covered in our latest report updated in June 2020.

Browse More Details Or Receive Free Sample Copy With Graphs & Charts: https://www.reportscheck.com/shop/2021-2026-report-on-global-thoracic-catheters-market-by-player-region-type-application-and-sales-channel/

The Thoracic Catheters production, market performance over past and present years, opportunity mapping, investment feasibility and growth orbits are specified in this research report. The regional markets share of every industry player, product type and application is studied which is as follows:

Top Companies Involved in Thoracic Catheters Industry are:MedtronicTeleflexSmiths MedicalAtriumMedelaRedaxAtmosSorinArgonCook MedicalPAHSCODiversatek

Top Product Types Evaluated are:CatheterAnalogDigital

Top Applications studied are:PneumothoraxPleural EffusionOthers

To derive the vital Thoracic Catheters Industry aspects like market share, revenue, production, demand various primary interviews and interactions are carried out with industry experts like VPs, CEOs, Marketing Managers, R&D Managers, distributors, national sales mangers of top companies. Primary and performance analysis is carried out by interviewing the distributors, traders, dealers and more. The most crucial segment like Thoracic Catheters Market competition and trends is studied in this report.

Ask Any Query, Request Custom Information or View Report TOC: https://www.reportscheck.com/shop/2021-2026-report-on-global-thoracic-catheters-market-by-player-region-type-application-and-sales-channel/

The report evaluates the positive and negative impact of ongoing situations on Thoracic Catheters Industry with forecast opportunities and CAGR value. The historical and present industry situations, market trends, technological innovations, regulations, upcoming technologies, and challenges are covered. The Thoracic Catheters Market revenue is expected to surpass US$ XX Million by 2021 with a growth rate of xx.xx% from 2021-2027.

Regional Perspective and Thoracic Catheters Analysis:

The market scope and regional division include North America, Europe, Asia-Pacific, Middle East & Africa, South America, and Rest of the World. The industry presence in the Asia-Pacific region is expected to expand at a good pace due to the increase in production facilities, existing players developing new opportunities and new players emerging in Thoracic Catheters Market. North America is expected to reach a higher market share followed by the European region. Demand for Thoracic Catheters products and its relevant applications across different market segments is growing rapidly.

Thoracic Catheters Market Analysis Based on Top Companies:

After the market competition and overview by top players, company profiles of every Thoracic Catheters Industry player is provided in detail. This segment covers the company overview, business portfolio, production details & description, vital financials, developments, SWOT analysis, and more. Top companies across the globe are profiled in this research study. The report can be customized based on the users choice and more players can be added as per requirements.

The forecast Thoracic Catheters industry vision covers the market size estimation, growth driving factors, risk analysis & mitigation, new entrants SWOT analysis, and investment feasibility.

Key Assessments & Thoracic Catheters Market Research Report Highlights:

Thanks for reading our article. For any queries, questions, or custom requirements feel free to reach us or contact our analyst. We offer the report as per the clients stated scenario.

Contact Us:

Olivia Martin

Marketing Manager

Email: [emailprotected]

Website:www.reportscheck.com

More:

COVID-19 Impact On Global Stem Cell Therapy Market Research Report Strategies, Shares, Trends, Growth Analysis Forecast to 2027 - Daily Research...

Animal Stem Cell Therapy Market Size By Product Analysis, Application, End-Users, Regional Outlook, Competitive Strategies And Forecast Up To 2026 -…

New Jersey, United States,- Latest update on Animal Stem Cell Therapy Market Analysis report published with extensive market research, Animal Stem Cell Therapy Market growth analysis, and forecast by 2026. this report is highly predictive as it holds the overall market analysis of topmost companies into the Animal Stem Cell Therapy industry. With the classified Animal Stem Cell Therapy market research based on various growing regions, this report provides leading players portfolio along with sales, growth, market share, and so on.

The research report of the Animal Stem Cell Therapy market is predicted to accrue a significant remuneration portfolio by the end of the predicted time period. It includes parameters with respect to the Animal Stem Cell Therapy market dynamics incorporating varied driving forces affecting the commercialization graph of this business vertical and risks prevailing in the sphere. In addition, it also speaks about the Animal Stem Cell Therapy Market growth opportunities in the industry.

Animal Stem Cell Therapy Market Report covers the manufacturers data, including shipment, price, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including Animal Stem Cell Therapy market size, volume and value, as well as price data.

Animal Stem Cell Therapy Market competition by top Manufacturers:

Animal Stem Cell Therapy Market Classification by Types:

Animal Stem Cell Therapy Market Size by End-user Application:

Listing a few pointers from the report:

The objective of the Animal Stem Cell Therapy Market Report:

Cataloging the competitive terrain of the Animal Stem Cell Therapy market:

Unveiling the geographical penetration of the Animal Stem Cell Therapy market:

The report of the Animal Stem Cell Therapy market is an in-depth analysis of the business vertical projected to record a commendable annual growth rate over the estimated time period. It also comprises of a precise evaluation of the dynamics related to this marketplace. The purpose of the Animal Stem Cell Therapy Market report is to provide important information related to the industry deliverables such as market size, valuation forecast, sales volume, etc.

Major Highlights from Table of contents are listed below for quick lookup into Animal Stem Cell Therapy Market report

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Read the original:

Animal Stem Cell Therapy Market Size By Product Analysis, Application, End-Users, Regional Outlook, Competitive Strategies And Forecast Up To 2026 -...

Orgenesis to Collaborate with Educell to Conduct Clinical Validation of Cell Therapies Using Orgenesis’ Proprietary POCare Technologies for the…

GERMANTOWN, Md., July 14, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (Orgenesis or the Company), a pioneering global biotech company committed to accelerating commercialization and transforming the delivery of cell and gene therapies (CGTs), today announces that it has entered into a Collaboration Agreement with Educell Ltd., a premier European cell therapy company. Under the agreement, the parties plan to conduct one or more collaborative cell-based research projects aligned with local medical centers.

The companies will leverage the Orgenesis Cell and Gene Therapy (CGT) Biotech Platform which includes point of care (POCare) Networks, POCare Therapeutics and a POCare Technologiessuite of proprietary and in-licensed technologies that have been engineered to create customized processing systems. The agreement is part of the Orgenesis strategy of growing and expanding the POCare Network, which includes leading hospitals and research institutes around the world. The first collaboration under the agreement will focus on the clinical development of CAR-T and whole cell-based vaccine platform for use in cancer immunotherapies.

Vered Caplan, CEO of Orgenesis, stated, This latest collaboration with Educell expands our activities in Europe and we believe that it should help us launch our therapies into additional European hospitals, as well as help Educell commercialize their therapies around the world. We also believe that this collaboration reinforces the significant value proposition and flexibility of our CGT Biotech Platform. We look forward to benefiting from the expertise of Educell as we seek to expand our automated T-cell culturing approach into clinical validation and commercialization phases.

Dr Miomir Kneevi, CEO of Educell, commented, We are excited to team with Orgenesis to potentially advance these breakthrough therapies into clinical trials using cutting edge technologies. This collaboration reflects our commitment to bringing new, effective and affordable cell and gene therapy products to cancer patients worldwide while highlighting Educells ability to ensure safety in the process and help to reduce overall manufacturing costs.

Together, the companies are working to address significant unmet market needs for producing novel cell therapies in a cost effective, high quality and scalable manner. The joint clinical development program seeks to provide safe, simplified, and cost-effective processing in an automated and controlled environment from start to finish with minimal operator intervention.

About EducellEducell Ltd, established 1997, is a company focusing on the development of cell therapy products and is a registered cell and tissue establishment. The company is preparing cell therapy products for the treatment of articular cartilage, vesicouretral reflux, regeneration of bone tissue and treatment of immunological disorders, which are in use within the University Medical Centre Ljubljana and other clinical institutions in Slovenia under the hospital exemption rule supervised by the Agency for Medicinal Products and Medical Devices of the Republic of Slovenia. The companys R&D department is dedicated to the development of innovative cell therapy products and also to the development of medical devices that enable stem cell isolation and application in the operation theatre.

Educells ImmunoArt cell therapy product was developed in 2014 and is based on ex vivo expanded allogeneic mesenchymal stromal/stem cells (MSC) isolated from bone marrow. Its immunomodulatory capacity has already been proven in the clinic for the treatment of graft versus host disease (GvHD) and Chrons disease. Additional information is available at: https://www.educell.si/en/

About OrgenesisOrgenesis is a pioneering global biotech company which is unlocking the full potential of personalized therapies and closed processing systems through its Cell & Gene Therapy Biotech Platform, with the ultimate aim of providing life changing treatments at the Point of Care to large numbers of patients at low cost. The Platform consists of: (a) POCare Therapeutics, a pipeline of licensed cell and gene therapies (CGTs), and proprietary scientific knowhow; (b) POCare Technologies, a suite of proprietary and in-licensed technologies which are engineered to create customized processing systems for affordable point of care therapies; and (c) POCare Network, a collaborative, international ecosystem of leading research institutes and hospitals committed to clinical development and supply of CGTs at the point of care. By combining science, technologies and a collaborative network, Orgenesis is able to identify the most promising new therapies and provide a pathway for them to reach patients more quickly, more efficiently and at scale, thereby unlocking the power of cell and gene therapy for all. Additional information is available at: http://www.orgenesis.com.

Notice Regarding Forward-Looking StatementsThis press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. These forward-looking statements involve substantial uncertainties and risks and are based upon our current expectations, estimates and projections and reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including, but not limited to, our reliance on, and our ability to grow, our point-of-care cell therapy platform, our ability to effectively use the net proceeds from the sale of Masthercell, our ability to achieve and maintain overall profitability, the development of our POCare strategy, the sufficiency of working capital to realize our business plans, the development of our transdifferentiation technology as therapeutic treatment for diabetes which could, if successful, be a cure for Type 1 Diabetes; our technology not functioning as expected; our ability to retain key employees; our ability to satisfy the rigorous regulatory requirements for new procedures; our competitors developing better or cheaper alternatives to our products and the risks and uncertainties discussed under the heading "RISK FACTORS" in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31 2019, and in our other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update any forward-looking statement for any reason.

Contact for Orgenesis:Crescendo Communications, LLCTel: 212-671-1021Orgs@crescendo-ir.com

Read the original here:

Orgenesis to Collaborate with Educell to Conduct Clinical Validation of Cell Therapies Using Orgenesis' Proprietary POCare Technologies for the...

Musculoskeletal Disorder Stem Cell Therapy Market Size By Product Analysis, Application, End-Users, Regional Outlook, Competitive Strategies And…

New Jersey, United States,- Latest update on Musculoskeletal Disorder Stem Cell Therapy Market Analysis report published with extensive market research, Musculoskeletal Disorder Stem Cell Therapy Market growth analysis, and forecast by 2026. this report is highly predictive as it holds the overall market analysis of topmost companies into the Musculoskeletal Disorder Stem Cell Therapy industry. With the classified Musculoskeletal Disorder Stem Cell Therapy market research based on various growing regions, this report provides leading players portfolio along with sales, growth, market share, and so on.

The research report of the Musculoskeletal Disorder Stem Cell Therapy market is predicted to accrue a significant remuneration portfolio by the end of the predicted time period. It includes parameters with respect to the Musculoskeletal Disorder Stem Cell Therapy market dynamics incorporating varied driving forces affecting the commercialization graph of this business vertical and risks prevailing in the sphere. In addition, it also speaks about the Musculoskeletal Disorder Stem Cell Therapy Market growth opportunities in the industry.

Musculoskeletal Disorder Stem Cell Therapy Market Report covers the manufacturers data, including shipment, price, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including Musculoskeletal Disorder Stem Cell Therapy market size, volume and value, as well as price data.

Musculoskeletal Disorder Stem Cell Therapy Market competition by top Manufacturers:

Musculoskeletal Disorder Stem Cell Therapy Market Classification by Types:

Musculoskeletal Disorder Stem Cell Therapy Market Size by End-user Application:

Listing a few pointers from the report:

The objective of the Musculoskeletal Disorder Stem Cell Therapy Market Report:

Cataloging the competitive terrain of the Musculoskeletal Disorder Stem Cell Therapy market:

Unveiling the geographical penetration of the Musculoskeletal Disorder Stem Cell Therapy market:

The report of the Musculoskeletal Disorder Stem Cell Therapy market is an in-depth analysis of the business vertical projected to record a commendable annual growth rate over the estimated time period. It also comprises of a precise evaluation of the dynamics related to this marketplace. The purpose of the Musculoskeletal Disorder Stem Cell Therapy Market report is to provide important information related to the industry deliverables such as market size, valuation forecast, sales volume, etc.

Major Highlights from Table of contents are listed below for quick lookup into Musculoskeletal Disorder Stem Cell Therapy Market report

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

The rest is here:

Musculoskeletal Disorder Stem Cell Therapy Market Size By Product Analysis, Application, End-Users, Regional Outlook, Competitive Strategies And...

Former U.S. Secretary of Energy and Texas Governor, Rick Perry, Names Two Texas Companies as Leading Innovators in the Fight Against COVID-19 -…

HOUSTON--(BUSINESS WIRE)--Celltex Therapeutics Corporation, a Houston, Texas-based biotechnology company and a leader in Mesenchymal Stem Cell (MSC) banking and technology, recently announced that it has received approval from the U.S. Food and Drug Administration (FDA) to proceed with the Companys COVID-19 Phase II clinical trial evaluating Celltex-produced autologous (ones own) adipose tissue(fat)-derived Mesenchymal Stem Cells (AdMSCs) to provide immune support and prevent COVID-19. Medistar Corporation, a medical real estate company specializing in healthcare projects, and researchers in Texas have developed an air conditioning system that can catch and kill coronavirus 2 (SARS-CoV-2) in an effort to help both essential workers, schools and the general public combat the COVID-19 pandemic.

Former United States Secretary of Energy and Texas Governor, Rick Perry, recently listed both companies promising technologies during a national cable news broadcast when he discussed potential treatments to protect the public from the coronavirus. As a vaccine can take years to develop, Rick Perry has been paying close attention to treatments and therapies that are both effective and available and wants to ensure that the public is aware that there is hope on the horizon with new medical technology.

With the continued spread of COVID-19, Americans are looking for immediate hope and want to hear a message from leaders that there are opportunities and therapies that are not too far out into the future and that can fight this virus, said Mr. Perry. Celltex Therapeutics clinical trials to demonstrate Celltexs MSCs ability to be a powerful preventative against COVID-19, as well as a development from another company, Medistar Corporation, which worked with researchers to create a biodefense filter that goes into HVAC systems and kills 99.8% of the virus. These are incredible breakthroughs that could help curb the spread of COVID-19 in peoples bodies and their environments. Concerning Medistars biodefense filter in particular, it could represent an opportunity to enable our kids to return to school in September.

Celltexs Phase II multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety and prophylactic efficacy of MSCs to prevent COVID-19 was approved to proceed by the FDA based on Celltexs long history of producing its own proprietary MSCs in its cGMP FDA-compliant lab for more than 9,000 therapies administered without any adverse reaction. Celltex is currently enrolling 200 subjects in the study who are classified as at higher risk for contracting COVID-19 (https://www.clinicaltrials.gov/ct2/show/NCT04428801) and who have not been infected. One hundred subjects will receive intravenous infusions of autologous MSCs produced by Celltex while 100 will receive placebo treatments. The primary efficacy endpoint of the study is to evaluate overall safety of Celltexs MSCs. The secondary objective is to demonstrate the efficacy of Celltexs MSCs as a prophylactic therapy for those at a high risk of contracting coronavirus to mitigate respiratory, pulmonary and pneumonia co-morbidities.

Celltex has dedicated years to researching safety and efficacy of using its own proprietary MSCs for those suffering from injuries, pain and maladies associated with autoimmune, vascular and other debilitating diseases, including inflammatory lung conditions, pneumonia and chronic obstructive pulmonary disease (COPD). Global studies utilizing MSCs have shown promising results for combatting symptoms and complications associated with COVID-19, and as a leading commercial MSC banking and technology company, Celltex has the unique ability to transition these initial findings into a clinical trial. I am optimistic that our findings will result in favorable outcomes that will improve lives today and for generations to come, said David G. Eller, Celltex Chairman and Chief Executive Officer.

Medistar Corporation and a team of researchers from University of Houston and Texas A&M University worked together to design and fabricate an efficient air disinfection system based on heated nickel (Ni) foam to catch and kill SARS-CoV-2. Virus test results at the Galveston National Laboratory revealed 99.8% of the aerosolized SARS-CoV-2 was caught and killed by a single pass through a Ni-foam-based filter when heated up to 200 C. Additionally, the same filter was also used to catch and kill 99.9% of Bacillus anthracis, an airborne spore. This study paves the way for preventing transmission of SARS-CoV-2 and other highly infectious airborne agents in closed environments, such as schools, daycares, hotels, restaurants, airplanes, office buildings, churches, cruise ships and more. The peer-reviewed study can be found published in Material Physics Today.

Monzer Houranis technology is the only technology proven to catch and kill actual SARS-CoV-2 on contact, instantaneously. When deployed, this technology will have a dramatic impact in helping decrease indoor transmission of COVID-19 and other biological pathogens, said Dr. Garrett Peel, MD, Executive VP of Medistar Corporation & Founding Partner of Integrated Viral Protection.

ABOUT CELLTEX THERAPEUTICS

Founded in 2011, Celltex Therapeutics Corporation is a Houston, Texas-based biotechnology company and a pioneer in Mesenchymal Stem Cell (MSC) technology. The company is the nations leading commercial MSC banking company and focuses on spearheading breakthroughs in regenerative medicine using MSCs. Celltex uses its own proprietary technology to isolate, cryopreserve and culture hundreds of millions of superior grade MSCs in its state-of-the-art, current Good Manufacturing (cGMP) and FDA-compliant laboratory. Celltex-produced MSCs are used in regenerative therapies for injuries and chronic pain, as well as many other conditions, including vascular, degenerative and autoimmune diseases. Celltexs intellectual property (IP) portfolio encompasses over 1,500 clients, who have received over 9,000 MSC therapies for various diseases without incurring any adverse events. To learn more about Celltex, visit http://www.celltexbank.com.

ABOUT MEDISTAR CORPORATION

Medistar Corporation is a real estate development company headquartered in Houston, Texas. As it has for over 45 years, Medistar specializes in the development, financing and acquisition of real estate across the United States. Complementing its longstanding focus of medical real estate development, Medistar actively develops multifamily, hospitality, entertainment, commercial, and mixed-use projects. In Houston, Medistar is developing the iconic 50-story Innovation Tower to complement its recently completed 35-story, 374-unit LATITUDE Med Center apartment tower and 22-story, 353-key InterContinental Houston Medical Center hotel at the Texas Medical Center. Please visit http://www.medistarcorp.com/ for more information.

Continued here:

Former U.S. Secretary of Energy and Texas Governor, Rick Perry, Names Two Texas Companies as Leading Innovators in the Fight Against COVID-19 -...

Autologous Stem Cell and Non-Stem Cell Based Therapies Market: What Effect is COVID 19 Bringing That Will Change the Industry Brainstorm Cell…

Autologous Stem Cell and Non-Stem Cell Based Therapies Market has witnessed continuous growth within the past few years and is projected to grow even more throughout the forecast period (2020 2027). The analysis presents a whole assessment of the market and contains Future trends, Current Growth Factors, attentive opinions, facts, historical information, and statistically supported and trade valid market information.

The report, titled Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market defines and briefs readers about its products, applications, and specifications. The research lists key companies operating in the global market and also highlights the key changing trends adopted by the companies to maintain their dominance. By using SWOT analysis and Porters five force analysis tools, the strengths, weaknesses, opportunities, and threats of key companies are all mentioned in the report. All leading players in this global market are profiled with details such as product types, business overview, sales, manufacturing base, competitors, applications, and specifications.

You Can Request A Demo Version of Report Before Buying (Higher Preference For Corporate Email ID User): https://www.worldwidemarketreports.com/sample/284124

Brainstorm Cell Therapeutics, Cytori, Dendreon Corporation, Fibrocell, Lion Biotechnologies, Caladrius Biosciences, Opexa Therapeutics, Orgenesis, Regenexx, Genzyme of the major organizations dominating the global market.(*Note: Other Players Can be Added per Request)

1. Industry outlookThis is where youll find the current state of the Autologous Stem Cell and Non-Stem Cell Based Therapies industry overall and where its headed. Relevant industry metrics like size, trends, life cycle, and projected growth included here. This report comes prepared with the data to back up your business idea. On a regional basis, the Global Autologous Stem Cell and Non-Stem Cell Based Therapies market has been segmented into Asia-Pacific, North America, Europe, Latin America, and the Middle East and Africa.

2. Target marketThis target market section of study includes the following:

User persona and characteristics: It includes demographics such as age, income, and location. It lets you know what their interests and buying habits are, as well as explain the best position to meet their needs.

Market size: How big is the potential Autologous Stem Cell and Non-Stem Cell Based Therapies market for your business? It brings to light the consumption in the Autologous Stem Cell and Non-Stem Cell Based Therapies industry by the type and application.

3. Competitive analysisDiscover your competitors. The report lets you know what youre up against, but it also lets you spot the competitions weaknesses. Are there customers that are underserved? What can you offer that similar businesses arent offering? The competitive analysis contains the following components:

Direct competitors: What other companies are offering similar products and services? Which companies are your true competitors?

Competitor strengths and weaknesses: What is your competition good at? Where do they fall behind? Get insights to spot opportunities to excel where others are falling short.

Barriers to entry: What are the potential pitfalls of entering the Autologous Stem Cell and Non-Stem Cell Based Therapies market? Whats the cost of entry? Is it prohibitively high, or easy to enter?

The window of opportunity:Does your entry into the Autologous Stem Cell and Non-Stem Cell Based Therapies industry rely on time-sensitive technology? Do you need to enter early to take advantage of an emerging market?

4. ProjectionsLikewise, We offered thoughtful, not hockey-stick forecasting.

Market share:We have given the consumption behavior of users. When you know how much can your future customers spend, then only youll understand how much of the Autologous Stem Cell and Non-Stem Cell Based Therapies industry you have a chance to grab, and here we came up with real stats and numbers.

Impact Analysis of COVID-19:The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into account the political, economic, social, and technological parameters.

Finally, It is one report that hasnt shied away from taking a critical look at the current status and future outlook for the consumption/sales of these products, by the end users and applications. Not forgetting the market share control and growth rate of the Autologous Stem Cell and Non-Stem Cell Based Therapies Industry, per application. Most noteworthy, this market analysis will help you find market blind spots.

About WMR

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends.

Contact Us:

Mr. ShahWorldwide Market ReportsSeattle, WA 98154,U.S.Email: [emailprotected]

Read the original:

Autologous Stem Cell and Non-Stem Cell Based Therapies Market: What Effect is COVID 19 Bringing That Will Change the Industry Brainstorm Cell...


...89101112...203040...